A5051926196- Metabolism and Genetic Disorders
- Alzheimer's disease research and treatments
- Parkinson's Disease Mechanisms and Treatments
- Enzyme Structure and Function
- Oral microbiology and periodontitis research
- Botulinum Toxin and Related Neurological Disorders
- Helicobacter pylori-related gastroenterology studies
- Diet and metabolism studies
- Nerve injury and regeneration
- Medicinal Plants and Neuroprotection
- Metabolomics and Mass Spectrometry Studies
- Diet, Metabolism, and Disease
- Prostate Cancer Treatment and Research
- Chemical Synthesis and Analysis
- Bioactive Compounds and Antitumor Agents
- Veterinary medicine and infectious diseases
- RNA and protein synthesis mechanisms
- Cholinesterase and Neurodegenerative Diseases
- Muscle metabolism and nutrition
- Receptor Mechanisms and Signaling
- Mitochondrial Function and Pathology
- biodegradable polymer synthesis and properties
- Biochemical and Molecular Research
- Pneumonia and Respiratory Infections
- Nutrition, Genetics, and Disease
Universidad de Zaragoza
2016-2022
Instituto de Investigación Sanitaria Aragón
2020-2021
Estación Experimental de Aula Dei
2016
Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons, process that current therapeutic approaches cannot prevent. In PD, the typical pathological hallmark accumulation intracellular protein inclusions, known as Lewy bodies and neurites, which are mainly composed α-synuclein. Here, we exploited high-throughput screening methodology to identify small molecule (SynuClean-D) able inhibit α-synuclein aggregation. SynuClean-D significantly reduces in vitro...
An increasing number of neurodegenerative diseases are being found to be associated with the abnormal accumulation aggregated proteins in brain. In Parkinson's disease, this process involves aggregation alpha-synuclein (α-syn) into intraneuronal inclusions. Thus, compounds that inhibit α-syn represent a promising therapeutic strategy as disease-modifying agents for neurodegeneration. The formation amyloid aggregates can reproduced vitro by incubation recombinant protein. However, is...
α-Synuclein (α-Syn) forms toxic intracellular protein inclusions and transmissible amyloid structures in Parkinson's disease (PD). Preventing α-Syn self-assembly has become one of the most promising approaches search for disease-modifying treatments this neurodegenerative disorder. Here, we describe capacity a small molecule (ZPD-2), identified after high-throughput screening, to inhibit aggregation. ZPD-2 inhibits aggregation wild-type A30P H50Q familial variants vitro at substoichiometric...
Synucleinopathies are a group of disorders characterized by the accumulation α-Synuclein amyloid inclusions in brain. Preventing aggregation is challenging because disordered nature protein and stochastic fibrillogenesis, but, at same time, it promising approach for therapeutic intervention these pathologies. A high-throughput screening initiative allowed us to discover ZPDm, smallest active molecule library more than 14.000 compounds. Although ZPDm structure highly related that previously...
Streptococcus pneumoniae (Sp) strain TIGR4 is a virulent, encapsulated serotype that causes bacteremia, otitis media, meningitis and pneumonia. Increased bacterial resistance limited efficacy of the available vaccine to some serotypes complicate treatment diseases associated this microorganism. Flavodoxins are proteins involved in several important metabolic pathways. The Sp flavodoxin (Spfld) gene was recently reported be essential for establishment rat model, which makes SpFld potential...
Antimicrobial resistant (AMR) bacteria constitute a global health concern. Helicobacter pylori is Gram-negative bacterium that infects about half of the human population and major cause peptic ulcer disease gastric cancer. Increasing resistance to triple quadruple H. eradication therapies poses great challenges urges development novel, ideally narrow spectrum, antimicrobials targeting pylori. Here, we describe antimicrobial spectrum family nitrobenzoxadiazol-based initially discovered as...
Human phenylalanine hydroxylase (PAH) is a metabolic enzyme involved in the catabolism of L-Phe liver. Loss conformational stability and decreased enzymatic activity PAH variants result autosomal recessive disorder phenylketonuria (PKU), characterized by developmental psychological problems if not treated early. One current therapeutic approach to treat PKU based on pharmacological chaperones (PCs), small molecules that can displace folding equilibrium unstable toward native state, thereby...
Phenylketonuria (PKU) is a rare metabolic disease caused by variations in human gene, PAH, encoding phenylalanine hydroxylase (PAH), and the enzyme converting essential amino acid into tyrosine. Many PKU-causing compromise conformational stability of encoded enzyme, decreasing or abolishing its catalytic activity, leading to an elevated concentration blood, which neurotoxic. Several therapeutic approaches have been developed treat more severe manifestations disorder, but they are either not...